ROS1 and cancer: Interestingly, the majority of the other germline predicted pathogenic variants, found with a significant increase in the BC patient group, clustered to the cytoplasmic tail of ROS1, similarly to the variants conferring resistance to classic TKIs in ROS1-rearranged cancers and for which novel drugs are currently developed [50,51].